Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay

Autor(es):Mostrar menos -

de Oliveira, Cristina Mendes ^[1] ; Musselwhite, Laura W. ^[2] ; Pantano, Naitielle de Paula ^[3] ; Vazquez, Fabiana Lima ^[1] ; Smith, Jennifer S. ^[4] ; Schweizer, Johannes ^[5] ; Belmares, Michael ^[5] ; Possati-Resende, Julio Cesar ^[3] ; Vieira, Marcelo de Andrade ^[6] ; Longatto-Filho, Adhemar ^{[1, 7, 8, 9]} ; Tavares Guerreiro Fregnani, Jose Humberto ^{[10, 11]}

Afiliação do(s) autor(es):Mostrar menos -

^[1] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos - Brazil

^[2] Duke Univ, Duke Canc Inst, Durham, NC - USA

^[3] Barretos Canc Hosp, Prevent Dept, Barretos - Brazil

^[4] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 - USA

^[5] Arbor Vita Corp, Fremont, CA - USA

^[6] Barretos Canc Hosp, Gynecol Dept, Barretos - Brazil

^[7] ICVS 3Bs Associated Lab Govt Portugal, Braga - Portugal

^[8] Univ Sao Paulo, Dept Pathol, Med Lab Med Invest LIM 14, Fac Med, Sao Paulo - Brazil

^[9] Univ Minho, Inst Life & Hlth Sci ICVS, Braga - Portugal

^[10] Barretos Canc Hosp, Teaching & Res Inst, Barretos - Brazil

^[11] AC Camargo Canc Ctr, Teaching & Learning Dept, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLoS One; v. 15, n. 4 APR 22 2020.
• Citações Web of Science: 0

Resumo

Cervical cancer is a significant public health problem, especially in low- and middle-income countries, where women have little access to cervical cancer screening; consequently 80% of cervical cancer related mortality occurs in these regions. The development of screening methods that need less infrastructure thus represents an urgent medical need. The study aims to compare the detection rates of high-risk human papillomavirus 16 and 18 E6 oncoprotein in urine, vaginal self-collected, and cervical scrapes of women using the OncoE6 (TM) Cervical Test and compare the HPV16 and/or HPV18 E6 detection rates with the HPV DNA testing. Paired urine, vaginal self-collected and cervical specimens were collected from 124 women who participated in cervical cancer screening or treatment in this proof-of-concept study and underwent to HPV16/18-E6 testing and high-risk HPV DNA testing prior to treatment of cervical neoplasia or cancer. Concordance between urinary, vaginal and cervical HPV16/18-E6 and HPV-DNA testing was evaluated for patients classified as negative group (<CIN2) and histological positive group (CIN2, CIN3 and invasive carcinoma). Overall, HPV16/18-E6 oncoprotein was detected in 30.6% of cervical samples, 20.3% of self-collected vaginal samples and 21% of urine samples. Regarding the clinical sensitivity, the HPV16/18-E6 oncoprotein was not detected in CIN2 cases, and was detected at low rates in CIN3 cases. The clinical sensitivity of the HPV16/18-E6 oncoprotein for detecting invasive cervical cancer was 70% for cervical scrapes, 55% for self-collected vaginal samples and 52% for urine samples. This study reports the urinary detection of E6 oncoprotein in vivo for the first time and our results suggest that this detection is only for invasive/microinvasive lesions. Then, further protocol development and standardization to achieve a clinical sensitivity for CIN2/3 detection close to what can be achieved for invasive lesions using the physician collected cervical is needed. (AU)

• Processo FAPESP: 16/19527-7 - Avaliação de novas tecnologias para detecção de HPV na urina - extensão de projeto de pesquisa "Bill and Melinda Gates Foundation"
• Beneficiário: José Humberto Tavares Guerreiro Fregnani
• Modalidade de apoio: Auxílio à Pesquisa - Regular